Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
Journal of Medical Sciences
  Year: 2010 | Volume: 10 | Issue: 2 | Page No.: 25-33
DOI: 10.3923/jms.2010.25.33
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Changes in Lipid Profiles in Two Groups of HIV-1 Infected Patients in Cameroon on Two Treatment Regimens with Either Efavirenz or Nevirapine, in Association with Reverse Transcriptase Inhibitors

N.F. Nguemaim, J. Mbuagbaw, T. Nkoa, G. Teto, G.R. Njitchouang, D.J. Pouomogne, A. Same-Ekobo and T. Asonganyi

Abstract:
The aim of this study was to determine the effect of two antiretroviral therapy regimens on lipid profiles. Patients were allocated to two treatment regimens: Nevirapine (NVP) + Stavudine (d4T) + Lamivudine (3TC) (n = 197) or Efavirenz (EFV) + Stavudine (d4T) + Lamivudine (3TC) (n = 181). Serum was prepared from blood samples collected before the start of treatment (Month 0) and at 24 months. Lipids and lipoproteins were measured using colorimetric enzyme assays or by calculation. Overall, there was an increase in all lipid parameters in patients on both treatment regimens at 24 months, although there were individual differences with respect to each lipid parameter that affected the atherogenicity indices for both regimens. Increase of high density lipoprotein cholesterol (HDLC) (42.82%) was significantly larger in patients on the NVP than on EFV (24.03%) (p<0.001), as opposed to Total Cholesterol (TC), triglycerides (TG) And Low Density Lipoprotein Cholesterol (LDLC) that were significantly lower in patient on NVP than on EFV; TG, Very Low Density Lipoproteins (VLDL) and LDLC increased in both regimens. These changes were not much affected by changes in viral load and CD4 cell levels. The changes in the atherogenicity indices showed that the regimen with NVP seems to have less risk of coronary heart disease compared to EFV.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    The in vivo and in vitro Developmental Toxicity and Teratogenicity of the Anti-AIDS Drugs (Human and Experimental Animal Studies)
  •    Effect of Antiretroviral Therapy on Lipid Metabolism in HIV/AIDS Subjects in Cameroon
  •    Lipid Profile of Infected Patients Treated with Highly Active Antiretroviral Therapy in Cameroon
How to cite this article:

N.F. Nguemaim, J. Mbuagbaw, T. Nkoa, G. Teto, G.R. Njitchouang, D.J. Pouomogne, A. Same-Ekobo and T. Asonganyi, 2010. Changes in Lipid Profiles in Two Groups of HIV-1 Infected Patients in Cameroon on Two Treatment Regimens with Either Efavirenz or Nevirapine, in Association with Reverse Transcriptase Inhibitors. Journal of Medical Sciences, 10: 25-33.

DOI: 10.3923/jms.2010.25.33

URL: https://scialert.net/abstract/?doi=jms.2010.25.33

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 

Curve Bottom